435 related articles for article (PubMed ID: 27846761)
1. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
3. A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders.
Yamakawa N; Fujimoto M; Kawabata D; Terao C; Nishikori M; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Ohmura K; Fujii T; Kitano T; Kondo T; Yurugi K; Miura Y; Maekawa T; Saji H; Takaori-Kondo A; Matsuda F; Haga H; Mimori T
J Rheumatol; 2014 Feb; 41(2):293-9. PubMed ID: 24334644
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
7. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients.
Kameda T; Dobashi H; Miyatake N; Inoo M; Onishi I; Kurata N; Mitsunaka H; Kawakami K; Fukumoto T; Susaki K; Izumikawa M; Nakashima S; Shimada H; Takeuchi Y; Haba R; Mano S; Onishi H; Imataki O; Matsunaga T
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1302-9. PubMed ID: 24515570
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.
Salloum E; Cooper DL; Howe G; Lacy J; Tallini G; Crouch J; Schultz M; Murren J
J Clin Oncol; 1996 Jun; 14(6):1943-9. PubMed ID: 8656264
[TBL] [Abstract][Full Text] [Related]
9. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Toyonaga H; Fukushima M; Shimeno N; Inokuma T
BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders.
Ejima-Yamada K; Oshiro Y; Okamura S; Fujisaki T; Mihashi Y; Tamura K; Fukushige T; Kojima M; Shibuya K; Takeshita M
Virchows Arch; 2017 Feb; 470(2):205-215. PubMed ID: 27864689
[TBL] [Abstract][Full Text] [Related]
13. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate-related lymphoproliferative disorder of the stomach in a patient with rheumatoid arthritis: a case of disease regression after methotrexate cessation.
Ikeda K; Nakamura T; Kinoshita T; Fujiwara M; Uose S; Someda H; Miyoshi T; Io K; Nagai K
Clin J Gastroenterol; 2016 Feb; 9(1):17-21. PubMed ID: 26733461
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-associated lymphoproliferative disorders of the tongue developing in patients with rheumatoid arthritis: a report of 2 cases and a review.
Hashimoto K; Nagao T; Saito T; Kinoshita H
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e1-5. PubMed ID: 24927637
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.
Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827
[TBL] [Abstract][Full Text] [Related]
17. Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD.
Kondo M; Murakawa Y; Moriyama M; Honda M; Sugiura T; Onoda K; Watanabe Y; Kakimaru H
Mod Rheumatol; 2021 Jan; 31(1):88-93. PubMed ID: 32075469
[TBL] [Abstract][Full Text] [Related]
18. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
[TBL] [Abstract][Full Text] [Related]
19. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective.
Harigai M
Mod Rheumatol; 2018 Jan; 28(1):1-8. PubMed ID: 28758827
[TBL] [Abstract][Full Text] [Related]
20. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
